Nesp Darbepoetin Alfa Injection

1. Indications and Usage
Anemia Due to Chronic Kidney Disease (CKD):
Indicated for the treatment of anemia associated with CKD in adult and pediatric patients.
Goal: To reduce the need for red blood cell (RBC) transfusions.
Anemia Due to Chemotherapy:
Indicated for the treatment of anemia in adult patients with non-myeloid malignancies where anemia is attributable to concurrent chemotherapy.
Limitation: Therapy is limited to patients with a planned chemotherapy duration of at least 2 months.
2. Dosage and Administration
Route of Administration:
For Intravenous (IV) or Subcutaneous (SC) Injection.
Dosage Principles:
Dosage must be individualized based on the patient’s response.
Recommended Dosage (CKD):
Starting Dose:
Hemodialysis Patients: 0.45 mcg/kg once weekly IV or SC, or 0.75 mcg/kg once every 2 weeks SC.
Non-Dialysis Patients: 0.45 mcg/kg once weekly IV or SC.
Dose Adjustment:
Adjust the dose to maintain Hb levels within the target range (typically 10–11 g/dL).
If Hb increases >1 g/dL (10 g/L) in any 2-week period, reduce the dose by at least 25%.
Withhold dose if Hb exceeds target range to avoid risks of thrombosis.
3. Mechanism of Action
EPO Receptor Agonist:
Darbepoetin alfa is a glycosylated analog of endogenous erythropoietin (EPO).
Enhanced Half-Life:
It contains 5 N-linked carbohydrate chains (compared to 3 in native EPO), which increases its molecular weight and serum half-life (approx. 3 times longer than epoetin alfa).
Erythropoiesis:
It binds to EPO receptors on bone marrow cells, stimulating the proliferation and differentiation of erythroid progenitor cells into red blood cells.
4. Safety and Warnings
Increased Risk of Mortality and Thrombosis:
ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access.
Black Box Warning: Safety is reduced when targeting Hb >11 g/dL.
Tumor Progression:
In patients with malignancy, ESAs may shorten overall survival and/or increase the risk of tumor progression or recurrence.
Severe Skin Reactions:
Serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported.
Pure Red Cell Aplasia (PRCA):
Rare cases of PRCA have occurred with ESA therapy.
5. Adverse Reactions
Most Common:
Hypertension, headache, arthralgia, nausea, edema, fatigue, and vomiting.
Serious Events:
Stroke, myocardial infarction, seizure, and thromboembolic events.
6. Drug Interactions
No Specific Interactions:
No formal drug-drug interaction studies have been conducted.
Concomitant Use:
Use caution with drugs that may interact with the ESA pathway or affect hemoglobin levels.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Darbepoetin alfa (165 amino acids with 5 N-linked carbohydrate chains).
Appearance: Clear, colorless to slightly yellow solution.
Storage:
Store at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake.